The Library

Correlation of currently used radiobiological parameters with local control and acute and late mucosal toxicity in randomised studies of altered fractionation for locally advanced head and neck cancer

Tools

Hartley, Andrew, Sanghera, Paul, Kazi, W., Mehanna, Hisham M., McConkey, Christopher C., Glaholm, John and Fowler, J. (Jack). (2011) Correlation of currently used radiobiological parameters with local control and acute and late mucosal toxicity in randomised studies of altered fractionation for locally advanced head and neck cancer. Clinical Oncology, Volume 23 (Number 1). pp. 29-33. ISSN 0936-6555

Full text not available from this repository.

Official URL: http://dx.doi.org/10.1016/j.clon.2010.08.007

Abstract

Aims: There has been a resurgence in interest in radiobiological modelling in head and neck cancer. The aim of this study was to determine if currently used parameters accurately predict both tumour and toxicity outcomes.

Materials and methods: Trials were identified from a recent meta-analysis of altered fractionation. The tumour biologically effective dose (tBED; alpha/beta= 10 Gy, t(k) [onset time of accelerated repopulation] = 22 days, t(p) [average doubling time during accelerated repopulation] = 3 days, alpha = 0.3 Gy(-1)), acute mucosal biologically effective dose (amBED; alpha/beta= 10 Gy, t(k)= 7 days, t(p)= 2.5 days, alpha = 0.3 Gy(-1)) and late mucosal biologically effective dose (ImBED; alpha/beta= 3 Gy) were calculated for each arm of each trial. The correlation between the absolute percentage difference in BED between treatment arms and the observed percentage difference in local control, acute grade 3 mucositis and late grade 3 mucosal reaction was then assessed.

Results: A strong correlation was observed between the percentage difference in tBED and the percentage difference in local control (P= 0.006). A trend towards a correlation was seen between the percentage difference in amBED and the percentage difference in acute grade 3 mucositis (P= 0.06). A significant correlation was observed between the percentage difference in ImBED and the percentage difference in grade 3 late mucosal toxicity (P= 0.02). However, a 15% decrease in ImBED between control and experimental arms of the study was necessary for any sparing of late mucosal toxicity to be observed.

Conclusions: Currently used parameters for tumour accurately predict outcomes in randomised trials of altered fractionation. Although the relationship may be more complex for late mucosal reaction, the presence of a correlation is noteworthy given the infrequent reporting or occurrence of this toxicity. In the future, radiobiological modelling with the addition of volumetric parameters will be highly relevant, given attempts to dose escalate with intensity-modulated radiotherapy in poor risk patients and de-escalate in patients with an excellent prognosis. (C) 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Item Type:

Journal Article

Subjects:

R Medicine > R Medicine (General)
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)

Divisions:

Faculty of Medicine > Warwick Medical School

Library of Congress Subject Headings (LCSH):

Mucous membranes -- Diseases, Head -- Cancer, Neck -- Cancer, Radiobiology -- Mathematical models, Squamous cell carcinoma

Journal or Publication Title:

Clinical Oncology

Publisher:

Elsevier Science London

ISSN:

0936-6555

Official Date:

February 2011

Dates:

Date	Event
February 2011	Published

Volume:

Volume 23

Number:

Number 1

Page Range:

pp. 29-33

Identification Number:

10.1016/j.clon.2010.08.007

Status:

Peer Reviewed

Publication Status:

Published

Access rights to Published version:

Restricted or Subscription Access

References:

[1] Kasibhatla M, Kirkpatrick J, Brizel D. How much radiation is
the chemotherapy worth in advanced head and neck cancer?
Int J Radiat Oncol Biol Phys 2007;68:1491e1495.
[2] Fowler J. Correction to Kasibhatla et al. (Int J Radiat Oncol Biol
Phys 2007;68:1491e1495). How much radiation is the
chemotherapy worth in advanced head and neck cancer? Int J
Radiat Oncol Biol Phys 2008;71:326e329.
[3] Lee I, Eisbruch A. Mucositis versus tumor control: the therapeutic
index of adding chemotherapy to irradiation of head
and neck cancer. Int J Radiat Oncol Biol Phys 2009;75(4):
1060e1063.
[4] Hartley A, Sanghera P,Glaholm J, et al. Radiobiologicalmodelling
of the therapeutic ratio for the addition of synchronous
chemotherapy to radiotherapy in locally advanced squamous
cell carcinoma of the head and neck. Clin Oncol
2010;22:125e130.
[5] Bourrhis J, Overgaard J, Audry H, et al. Hyperfractionated or
accelerated radiotherapy in head and neck cancer: a metaanalysis.
Lancet 2006;368(9538):843e854.
[6] Bourrhis J, Lapeyre M, Tortochaux J, et al. Phase III randomized
trial of very accelerated radiation therapy compared with
conventional radiation therapy in squamous cell head and
neck cancer: a GORTEC trial. J Clin Oncol 2006;24:2873e2878.
[7] Horiot JC, Le Fur R, N’Guyen T, et al. Hyperfractionation versus
conventional fractionation in oropharyngeal carcinoma: final
analysis of a randomized trial of the EORTC cooperative group
of radiotherapy. Radiother Oncol 1992;25:231e241.
[8] Dische S, Saunders M, Barrett A, et al. A randomised multicentre
trial of CHART versus conventional radiotherapy in
head and neck cancer. Radiother Oncol 1997;44(2):
123e136.
[9] Bentzen S, Saunders M, Dische S, et al. Radiotherapy-related
early morbidity in head and neck cancer: quantitative clinical
radiobiology as deduced from the CHART trial. Radiother Oncol
2001;60:123e135.
[10] Poulsen MG, Denham JW, Peters LJ, et al. A randomised trial of
accelerated and conventional radiotherapy for stage III and IV
squamous carcinoma of the head and neck: a Trans-Tasman
Radiation Oncology Group study. Radiother Oncol 2001;60:
113.
[11] Overgaard J, Hansen H, Specht L, et al. Five compared with six
fractions per week of conventional radiotherapy of squamouscell
carcinoma of head and neck: DAHANCA 6&7 randomised
controlled trial. Lancet 2003;362:933e940.
[12] Fu K, Pajak T, Trotti A, et al. A Radiation Therapy Oncology
Group (RTOG) phase III randomized study to compare
hyperfractionation and two variants of accelerated fractionation
to standard fractionation radiotherapy for head and
neck squamous cell carcinomas: first report of RTOG 9003.
Int J Radiat Oncol Biol Phys 2000;48:7e16.
[13] Horiot J, Bontemps P, van den Bogaert W, et al. Accelerated
fractionation (AF) compared to conventional fractionation
(CF) improves locoregional control in the radiotherapy of
advanced head and neck cancers: results of the EORTC 22851
randomised trial. Radiother Oncol 1997;44:111e121.
[14] Fakhry C, Westra W, Li S, et al. Improved survival of patients
with human papillomavirus-positive head and neck squamous
cell carcinoma in a prospective clinical trial. J Natl
Cancer Inst 2008;100:261e269.
[15] Caudell J, Meredith R, Spencer S, et al. Margin on gross tumor
volume and risk of local recurrence in head and neck cancer.
Int J Radiat Oncol Biol Phys 2010;76:164e168.
[16] Lee I. In reply to Dr Hartley. Int J Radiat Oncol Biol Phys
2009;75:315.
[17] Dorr W, Hamilton C, Boyd T, et al. Radiation induced changes
in cellularity and proliferation in human oral mucosa. Int J
Radiat Oncol Biol Phys 2002;52:911e917.
[18] Fowler JF, Harari PM, Leborgne F, et al. Acute radiation reactions
in oral and pharyngeal mucosa: tolerable levels in
altered fractionation schedules. Radiother Oncol 2003;69:
161e168.
[19] Fowler JF. Is there an optimum overall time for head and neck
radiotherapy. A review with new modelling. Clin Oncol 2007;
19:8e22.